New vaccine aims to control or cure chronic hepatitis b
NCT ID NCT03038802
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests a new therapeutic vaccine (Hepadvax) in 40 adults with chronic hepatitis B. The vaccine is designed to boost the immune system to control or possibly clear the virus. Researchers will monitor safety, viral load, and immune responses compared to a standard hepatitis B vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Therapeutic hepatitis B vaccine (Hepadvax) with Advax-2 adjuvant
What this could lead to
If successful, this vaccine could help control or even clear chronic hepatitis B infection, reducing the need for lifelong antiviral medication.
What could go wrong
This is an early phase 1/2 trial with only 40 participants, so results may not apply broadly. The vaccine may not effectively reduce viral load or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ARASMI
Adelaide, South Australia, 5046, Australia
Contact
Contact